GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Cash-to-Debt

Lipocine (Lipocine) Cash-to-Debt : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lipocine's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lipocine could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Lipocine's Cash-to-Debt or its related term are showing as below:

LPCN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.49   Med: No Debt   Max: No Debt
Current: No Debt

During the past 13 years, Lipocine's highest Cash to Debt Ratio was No Debt. The lowest was 1.49. And the median was No Debt.

LPCN's Cash-to-Debt is ranked better than
99.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs LPCN: No Debt

Lipocine Cash-to-Debt Historical Data

The historical data trend for Lipocine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lipocine Cash-to-Debt Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 3.52 19.31 No Debt No Debt

Lipocine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Lipocine's Cash-to-Debt

For the Biotechnology subindustry, Lipocine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lipocine's Cash-to-Debt falls into.



Lipocine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lipocine's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Lipocine had no debt (1).

Lipocine's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Lipocine had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipocine  (NAS:LPCN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Lipocine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lipocine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103